Review article: Functional dyspepsia and pregnancy-Effects and management in a special population
- PMID: 37129241
- DOI: 10.1111/apt.17534
Review article: Functional dyspepsia and pregnancy-Effects and management in a special population
Abstract
Background: Around 10% of Americans meet the Rome IV criteria for functional dyspepsia (FD), with a significantly higher rate in women. FD also has a higher prevalence in women below the age of 50, suggesting that women who are affected are likely to be of reproductive age. Unfortunately, there is a lack of research or evidence-based guidelines on managing FD in pregnancy.
Aims and methods: To address this issue, we aimed to perform a systematic review of the interactions between FD and pregnancy and managing pre-existing FD in the peripartum and post-partum phases using current lifestyle, pharmacological, non-pharmacological and alternative medicine interventions.
Results: Due to the lack of Rome IV FD-specific data in pregnancy, we instead performed a narrative review on how existing FD interventions could be extrapolated to the pregnant population. Where possible we use the highest level of available evidence or official guidelines to answer these questions, which often involves synthesising treatment and safety evidence of these interventions in other diseases during pregnancy. Finally, we highlight current substantial knowledge gaps requiring further research for the safe management of a pregnant patient with pre-existing FD.
Conclusions: Overall, despite the paucity of knowledge of treating FD during pregnancy, providers can mitigate this uncertainty by planning ahead with the patient. Patients should ideally minimise treatment until after breastfeeding. However, interdisciplinary resources are available to ensure that minimal-risk interventions are maximised, while interventions with more risks, if necessary, are justifiable by both the patient and the care team. Future investigations should continue to elicit the mechanistic relationship between FD and pregnancy while cautiously expanding prospective research on promising and safe therapies in pregnant patients with pre-existing FD.
© 2023 John Wiley & Sons Ltd.
Comment in
-
Editorial: Functional dyspepsia in pregnancy-Distinct approaches to a special population.Aliment Pharmacol Ther. 2023 Jul;58(2):250-251. doi: 10.1111/apt.17553. Aliment Pharmacol Ther. 2023. PMID: 37352153 No abstract available.
References
REFERENCES
-
- Stanghellini V. Functional dyspepsia and irritable bowel syndrome: beyond Rome IV. Dig Dis (Basel, Switzerland). 2017;35(Suppl 1):14-7. https://doi.org/10.1159/000485408
-
- Sayuk GS, Gyawali CP. Functional dyspepsia: diagnostic and therapeutic approaches. Drugs. 2020;80(13):1319-36. https://doi.org/10.1007/s40265-020-01362-4
-
- Enck P, Azpiroz F, Boeckxstaens G, Elsenbruch S, Feinle-Bisset C, Holtmann G, et al. Functional dyspepsia. Nat Rev Dis Primers. 2017;3(1):17081. https://doi.org/10.1038/nrdp.2017.81
-
- Ford AC, Marwaha A, Sood R, Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut. 2015;64(7):1049-57. https://doi.org/10.1136/gutjnl-2014-307843
-
- Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation Global Study. Gastroenterology. 2021;160(1):99-114.e3. https://doi.org/10.1053/j.gastro.2020.04.014
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical